The protective effect of vitexinin septic encephalopathy by reducing leukocyte-endothelial adhesion and inflammatory response

Haiquan Cao¹, Xiaojuan Wang², Bing Zhang³, Meiping Ren⁴

¹Department of Critical Care Medicine, ²Department of Endocrinology, ³Orthopaedics, The Second Clinical Medical College of North Sichuan Medical College/Nanchong Central Hospital, Nanchong, China; ⁴Department of Pharmacology, Southwest Medical University, Luzhou, China

Contributions: (I) Conception and design: H Cao, X Wang; (II) Administrative support: H Cao; (III) Provision of study materials or patients: M Ren, B Zhang, X Wang; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: H Cao, M Ren, B Zhang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Haiquan Cao. Department of Critical Care Medicine, The Second Clinical Medical College of North Sichuan Medical College/Nanchong Central Hospital, Nanchong 637000, China. Email: 3112049007@qq.com.

Background: Despite advances in therapeutic strategies and critical care management, septic encephalopathy (SE) is still a leading cause of infection-associated death in intensive care units (ICUs). Vitexin, a flavonoids compound, exerts an anti-inflammatory effect through inhibition of proinflammatory cytokines and signaling pathways. This study aimed to explore the anti-inflammatory effects of vitexin in SE and the underlying mechanisms.

Methods: An SE-induced C57BL/6 mouse model was established via cecal ligation and puncture (CLP). Western blotting was performed to evaluate the protein expression levels of Chemokine (C-X-C motif) ligand 1 (CXCL1), fractalkine (CX3CL1), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, NF-κB p65, p-NF-κB p65, and tumor necrosis factor-α (TNF-α). Flow cytometry was used to detect the expressions of CD11a/CD18, CD11b/CD18, ICAM-1, and adherent leukocyte. The expression of ICAM-1 was detected by immunohistochemistry. An enzyme-linked immunosorbent assay was performed to evaluate the expression of monocyte chemotactic protein-1 (MCP-1), Interleukin (IL)-6, IL-8, and IL-10.

Results: In this study, we found that vitexin significantly downregulated the expression of brain endothelial chemokines CXCL1 and CX3CL1 in CLP mice, exerting a potential anti-inflammatory against SE. Our data also showed that vitexin alleviated SE primarily by relying on reducing leukocyte-endothelial adhesion via the mediation of adhesion molecules. Moreover, vitexin suppressed the expression of proinflammatory cytokines, such as MCP-1, IL-6, IL-8, TNF-α, and NF-κB p65, in the CLP mice, while the expression of the anti-inflammatory cytokine IL-10 was elevated.

Conclusions: Overall, our study demonstrated the protective effect vitexin exerts in SE by reducing leukocyte-endothelial adhesion and inflammatory response. These findings offer a molecular basis for the potential application of vitexin in the treatment of SE and other inflammatory-mediated and immune-mediated disorders.

Keywords: Vitexin; leukocyte-endothelial adhesion; inflammatory cytokines; septic encephalopathy (SE)
**Introduction**

Septic encephalopathy (SE) is the most common cause of admission to intensive care units (ICUs) and is a leading cause of infection-associated death (1). SE, a cerebral disorder, stems from changes in metabolic and cellular signaling that are mediated by inflammatory components (2). In recent decades, advances in therapeutic strategies and critical care management of SE have been made; however, the currently available therapeutic strategies are still limited and the underlying pathogenic mechanism has yet to be fully illuminated (3,4).

Cell adhesion is a central process in creating a stable environment for cell growth, differentiation, and migration (5). Adhesion molecules are expressed on the cell surface of all tissues, and each has specific characteristics. They trigger intracellular pathways and participate in the control of basic physiological processes (6,7). Under normal conditions, the main function of endothelial cells is to maintain the anti-adhesive surface by adjusting and suppressing coagulation and restraining leukocyte adhesion (8,9). Many studies have demonstrated that the activation of injured or infected endothelial cells can lead to a decrease in the levels of adhesion molecules and chemokines, causing leukocytes to aggregate to specific sites of inflammation or, immune response (10). Despite the accumulation and activation of endothelial cells being signs of an effective host response to infection, inflammation, and tissue damage (a key step in which is leukocyte adhesion to endothelial cells), leukocyte-endothelial interaction may be harmful for the host (11). Studying the adhesion molecules and chemokines that are recruited by leukocytes to endothelial cells may help to understand the molecular regulation of leukocyte-endothelial adhesion interactions. E-selectin and P-selectin, for instance, interact with glycosylated ligands; intercellular adhesion molecule-1 (ICAM-1) interacts with lymphocyte function-associated antigen 1; and vascular cell adhesion molecule-1 (VCAM-1) binds to very late antigen 4 (12,13). Blockade of receptor-ligand interactions serves as the most direct approach to inhibiting leukocyte adhesion to endothelial cells, and provides a potential way to reduce vascular and tissue injury in a variety of inflammatory and immune diseases, including SE (14).

Vitexin, a c-glycosylated flavone, can be isolated from various plants such as pearl millet, hawthorn, and pigeon pea. Recently, owing to its broad pharmacological potential, including anti-tumor, antioxidant, and anti-inflammatory activity, vitexin has drawn a significant amount of attention (15). He et al. reported that vitexin induced apoptosis by inhibiting autophagy in hepatocellular carcinoma through activating the c-Jun-N-terminal kinase (JNK) signaling pathway (16). Furthermore, other studies have reported that the anti-inflammatory effect exhibited by vitexin largely depends on the inhibition of proinflammatory molecule secretion, including that of monocyte chemotactic protein-1 (MCP-1), Interleukin (IL)-6, and the tumor necrosis factor-α (TNF-α), as well as an increase in the anti-inflammatory cytokine IL-10 (17-20). In this study, the anti-inflammatory effects of vitexin on SE were investigated, and the promise of vitexin as a new natural anti-inflammatory candidate for the treatment of SE was evidenced.

We present the following article in accordance with the ARRIVE reporting checklist (available at http://dx.doi.org/10.21037/apm-20-1211).

**Methods**

**CLP model and drug treatment**

Wild-type C57BL/6 male mice were purchased from Beijing Huafulang Bioscience CO. INC. (Beijing, China). The Committee for Animal Experiments of The Second Clinical Medical School Affiliated to North Sichuan Medical College/Nanchong Central Hospital approved all of the experiments involving animals. This study also conformed to the NIH guidelines for the care and use of animals. CLP was used to induced SE in the mice, and comparisons were made with sham-operated controls. In brief, chloral hydrate (400 mg/kg body weight) was administered to anesthetize the mice. A midline incision was made to expose the cecum. Next, the cecum was ligated to the distal end of the ileocecal valve before an 18-gauge needle was used to puncture a hole to cause feces to enter into the enteroceola (21). The mice were intravenously administered with either vitexin or not. The control group was sham-operated.

**Real-time quantitative RT-PCR**

Mouse brain endothelial cells were isolated, as reported previously. Snap-freezing was performed using liquid nitrogen, and the cells were stored at −80 ℃ until use (22). A TRIzol reagent kit (Invitrogen, Beijing, China) was used to isolate total RNA, following the manufacturer’s protocol. PrimeScript RT reagent Kit (TakaRa, Dalian, China) was used to carry out reverse transcription following the manufacturer’s protocol. The 2 SYBR Premix Ex...
Taq™ II (TakaRa, Dalian, China) was used to assemble the quantitative real-time polymerase chain reactions (qRT-PCRs), which were subjected to the protocol as follows: 30 s at 95 °C, 40 cycles of 10 s at 95 °C, 30 s at 60 °C and 30 s at 72 °C. The melting curve was obtained using temperatures from 65 to 95 °C in 1 °C/10 s increments. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used for normalization. The \(2^{-\Delta\Delta Ct}\) method was applied to analyze relative changes in the levels of mRNA expression (23).

The primer sequences used were as follows: Chemokine (C-X-C motif) ligand 1 (CXCL1), forward primer CGTTGACATCCGTAAAGACC, reverse primer AACAGTCCGGCTAGAAGCAC; fractalkine (CX3CL1), forward primer CTACTAGGAGCTGCGACACG, reverse primer AAGCCACTGGGATTCGTGAG; glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward primer CGGAGTCAACGGATTTGGTCGTAT, reverse primer AGCCTTCTCCATGGTGGTGAAGAC.

**Western blot**

The protein extracted from the mouse brain endothelial cells was used for western blotting. RIPA lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China) was used to extract cellular proteins following the instructions of the manufacturer. The BCA Protein Assay Kit was employed to detect the protein concentrations. Next, protein separation was performed with 10% dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Following that, electroblotting was carried out to transfer the separated proteins to polyvinylidene difluoride (PVDF) membranes (Merck Millipore). Then, blocking with 5% skim milk in Tris-buffered saline Tween (TBST) was performed for 1 h.

The following antibodies were used: anti-CXCL1 (ab9955, 1:1,000, Abcam), anti-CX3CL1 (ab25088, 1:1,000, Abcam), anti-ICAM-1 (ab109361, 1:1,000, Abcam), anti-VCAM-1, (ab134047, 1:2,000, Abcam), anti-E-selectin (ab2497, 1:1,000, Abcam), anti-NF-κB p65 (ab16502, 1:1,000, Abcam), anti-p-NF-κB p65 (ab86299, 1:2,000, Abcam), and TNF-α (ab1973, 1:1,000, Abcam), and anti-GAPDH (Zenbio, Chengdu, China).

**Flow cytometry**

Before the mice were decapitated, peripheral blood samples were obtained for flow cytometry analysis, as previously reported (24). First, 100 μL of whole blood were gently mixed with 10 μL of anti-mouse mAbs (PE-anti mouse CD11a/CD18, PE-anti mouse CD11b/CD18, and PE-anti mouse ICAM-1). The mixture was then incubated for 20 min at room temperature in the dark.

**Immunohistochemistry**

The mice were anesthetized and via transcardial perfusion, fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS). After that, the brains were wholly fixed with 4% paraformaldehyde for 24 h, then embedded in paraffin and sectioned. Xylene was used to separate the paraffinized sections before rehydration with gradient ethanol. Next, 10 mM citric acid buffer was used to extract the antigen, after which the tissue sections were kept in an incubator with 3% \(\text{H}_2\text{O}_2\) for 10 min and then sealed for 1 h at room temperature. The heart tissue sections were incubated overnight with an anti-ICAM-1 antibody (Abcam, Cambridge, UK), after which they were exposed to fluorescent secondary antibodies following the instructions of the manufacturer. The corresponding secondary antibody was incubated at room temperature for 1 h. Finally, an Olympus DX51 fluorescence microscope (Olympus, Tokyo, Japan) was used to observe the images, and data analysis was performed using Image-Pro Plus 6.0 (Media Cybernetics, USA).

**Enzyme-linked immunosorbent assay (ELISA) assay**

The ELISA assay was used to quantify the levels of MCP-1, IL-6, IL-8, and IL-10 protein. The total protein in the cell lysate extracted from the peripheral blood of the mice was measured with the QuantiPro™ BCA Assay Kit (Sigma, The Netherlands) following the manufacturer’s instructions. The DuoSet ELISA Development kit (R&D) was employed to measure the protein expressive levels of MCP-1, IL-6, IL-8, and IL-10 in the cell lysates following the protocol of the manufacturer. The protein content was normalized by total protein.

**Statistical analysis**

Each experiment in this study was carried out in triplicate, and the data were expressed as mean ± SD. Statistical analyses were conducted using IBM SPSS Statistics 25.0. (IBM, Armonk, USA). The differences between the two groups were analyzed by Student’s \(t\)-test. The significance of differences between treatment groups was analyzed using one-way analysis of variance (ANOVA). P<0.05 was
Results

Vitexin downregulates the expression of brain endothelial chemokines

Septic injury has been reported to increase the expression levels of chemokines CXCL1 and CX3CL1 in brain endothelial cells (14). Western blotting revealed that the expression levels of CXCL1 and CX3CL1 were significantly higher in the mice with CLP-induced sepsis than in the control group (Figure 1). Moreover, after treatment with vitexin, the expression levels of CXCL1 and CX3CL1 were significantly lower than CLP-induced sepsis group (Figure 1). These results suggested that vitexin might have protective effects on SE.

Vitexin inhibits leukocyte adhesion to endothelial cells

β2 integrins are the main cell surface adhesion molecules expressed in leukocytes and are responsible for mediating leukocytes adhesion to endothelial cells through binding to ICAM-1 (25). This study demonstrated that the leukocytic expression of CD11a/CD18 and CD11b/CD18 in the peripheral blood of the mice detected by flow cytometry was increased by CLP-induced sepsis, while vitexin successfully neutralized this rise (Figure 2A,B). Meanwhile, leukocytic expression of ICAM-1 was activated after CLP, while this activation was inhibited by vitexin treatment (Figure 2C).

Several studies have reported that ICAM-1, VCAM-1, and E-selectin to be endothelial adhesion proteins that are transcriptionally regulated by cytokines or other inflammatory mediators (13). Our results showed that the protein expression levels of ICAM-1, VCAM-1, and E-selectin were elevated by CLP-induced sepsis, while these effects successfully alleviated by vitexin (Figure 3A,B,C,D). The results of immunohistochemistry also confirmed that vitexin held the potential to neutralize the increased expression level of ICAM-1 in the CLP mice (Figure 3E). Moreover, the treatment of vitexin significantly alleviated the increased number of adherent leukocytes to CLP-induced brain vessels (Figure 3F). These data demonstrated that vitexin may suppress leukocyte-endothelial adhesion through the inhibition of the β2 integrin/ICAM-1 signaling pathway and endothelial adhesion protein expression.

Vitexin mediates inflammatory cytokine expression

Previous studies have reported that the levels of
Proinflammatory cytokines are highly elevated in the peripheral blood plasma of sepsis patients (26,27). In line with the findings of the previous studies, our data demonstrated that the expression of MCP-1, IL-6, and IL-8 was significantly upregulated by CLP-induced sepsis, while vitexin was able to alleviate these rises (Figure 4A,B,C). Moreover, after treatment with vitexin, the expression level of IL-10 was increased in comparison with the CLP group (Figure 4D). These results suggested that vitexin could simultaneously reduce proinflammatory cytokine expression and increase anti-inflammatory cytokine expression.

**Vitexin suppresses p-NF-κB p65 and TNF-α activation**

In the pathophysiology of sepsis, NF-κB p65 plays a key role in proinflammatory gene transcription (28). TNF-α also acts as a principal activator of the inflammatory cascade (29). The present data demonstrated that the expression levels of p-p65/p-65 and TNF-α were significantly elevated by CLP-induced sepsis, while vitexin could significantly alleviate these increases (Figure 5A,B,C). These data suggested that the protective effects on sepsis might attributed in part to the inhibition of p-p65/p-65 and TNF-α by vitexin.

**Figure 2** Effect of vitexin on β2 integrin/ICAM-1 pathway. The expression of CD11a/CD18 (A), CD11b/CD18 (B), and ICAM-1 (C) was detected by flow cytometry. Data are expressed as the mean ± SD, from three independent experiments. *, P<0.05 vs. the control group; #, P<0.05 vs. the CLP group.
Figure 3 Effect of vitexin on endothelial adhesion molecule expression. (A) The expression of ICAM-1, VCAM-1, and E-selectin was evaluated by western blotting. The histogram shows the relative expression of ICAM-1 (B), VCAM-1 (C), and E-selectin (D). (E) The expression of ICAM-1 was detected by immunohistochemistry. Magnification, 400×. (F) The expression of adherent leukocytes was detected by flow cytometry. Data are expressed as the mean ± SD, from three independent experiments. *, P<0.05 vs. the control group; #, P<0.05 vs. the CLP group.

Figure 4 Effect of vitexin on pro-/anti-inflammatory cytokine expression. The expression of MCP-1 (A), IL-6 (B), IL-8 (C) and IL-10 (D) was evaluated by ELISA. Data are expressed as the mean ± SD, from three independent experiments. *, P<0.05 vs. the control group; #, P<0.05 vs. the CLP group. ELISA, enzyme-linked immunosorbent assay.
Discussion

Natural compounds can be valuable resources for the prevention and treatment of various diseases, including sepsis. Honokiol, which is derived from Magnolia officinalis, has been showed to possess anti-inflammatory and antioxidant properties. A study by Li revealed that honokiol could antagonize sepsis-associated acute kidney injury partially through blocking the NF-κB signaling pathway (30). The progress of septic shock can be reversed by α-iso-cubebenol, which triggers numerous protective downstream signaling pathways, enhancing microbial killing and maintaining organ function and leukocyte survival (31). Meanwhile, wild bitter gourd can reduce fat accumulation and improve low blood glucose in sepsis, as well as reduce inflammatory markers in mice with sepsis (32). Recently, vitexin has been investigated for its broad variety of pharmacological effects, including anti-cancer, anti-oxidant and anti-inflammatory properties (15). For instance, vitexin was shown to trigger apoptosis in human esophageal cancer cells EC-109, leukemia cells U937, and oral cancer cells OC2, exerting its potential against tumor growth (33-35). Furthermore, vitexin significantly reduced the levels of TNF-α and IL-17 in pleural fluid leakage in a carrageenan-induced pleurisy mouse model, and it has exhibited an analgesic ability in several inflammatory pain animal models (17,36). These results suggest that vitexin may hold potential for treating diseases involving inflammation. Among its variety of attributes, the effect vitexin has on inflammation has drawn considerable attention, possibly because of its ability to regulate proinflammatory/anti-inflammatory cytokines and signaling pathways, such as IL-6, IL-8, IL-10, TNF-α, and NF-κB (15). Despite the many existing possibilities regarding the therapeutic potential of vitexin, its mechanisms deserve more systematic study, which may eventually contribute to the pharmacotherapy of various disease conditions. Here, we set out to investigate the therapeutic effects of vitexin in SE as well as the underlying molecular and cellular mechanisms associated with these effects, and to obtain experiment-based evidence of the possible value of vitexin as a novel natural anti-inflammatory candidate for the treatment of SE.

Leukocyte-endothelial cell adhesion is a crucial event in host defense and tissue damage repair; however, in some pathological conditions, this interaction may lead to organ dysfunction and tissue and vascular damage. Many studies have demonstrated that blockade of leukocyte adhesion to endothelium molecules has the potential to combat inflammatory-mediated and immune-mediated injury in various diseases (10). Simvastatin, for instance, showed a potent and effective endothelium-protective ability that reduced leukocyte-endothelial cell adhesion in rats, which suggests it has anti-inflammatory potential besides its well-known lipid-lowering effect (37). Targeting formyl peptide receptor 2 reduced leukocyte-endothelial cell adhesion in a murine stroke model and exerted a potential effect against excess inflammation (38). Moreover, sarpogrelate hydrochloride was shown to inhibit vascular inflammation in obesity, possibly by inactivating leukocyte adhesion to...
endothelial cells (39). Recently, a number of studies have investigated the molecular events associated with leukocyte-endothelial cell adhesion that contribute to the development of SE, which is a critical determining factor of sepsis-related mortality (14,40-42). These results support the idea that leukocyte-endothelial cell adhesion serves a role in linking vascular inflammation to brain damage, and provide rationale therapeutic strategies for the treatment of SE.

CX3 chemokines play a crucial role in leukocyte activation and subsequently promote their adhesion to endothelial cells (43). In a previous study, Roy et al. reported that, during encephalomyelitis, leukocyte-endothelial cell adhesion induced CXCL1 family cytokines in the brain (44). Furthermore, a research paper by Wang et al. further reported a significant increase in CXCL1 and CX3CL1 expression in brain microvessels during sepsis (14). Our findings are consistent with those of earlier studies and show that CXCL1 and CX3CL1 expression was increased in CLP-induced sepsis. More importantly, the data showed that vitexin was able to significantly decrease the expression levels of both CXCL1 and CX3CL1 in CLP-induced sepsis compared with the non-treated group, indicating that vitexin might hold potential for the treatment of SE.

To date, of the integrin adhesion receptor family, only five members have been shown to have involvement in the adhesion of leukocytes to endothelial cells, including β2 leukocyte integrin (CD11a/CD18, CD11b/CD18, and CD11c/CD18) and β1 integrin proteins VLA-4 (α4β1, CD49d/CD29) and α4β7. Leukocyte adhesion to endothelial cells relies primarily on CD11a/CD18 and CD11b/CD18 binding to endothelial ligand ICAM-1 (9,13). In addition, previous research has demonstrated that CXCL1 promotes endothelial activation and leukocyte adhesion via the β2 integrin/ICAM-1 pathway (14). Consistent with above results, our data shows that the levels of CD11a/CD18, CD11b/CD18 and ICAM-1 in the peripheral blood of the mice were increased by CLP-induced sepsis, while vitexin was able to neutralize these increases. These data suggest that intexin may possess the ability to inhibit leukocyte adhesion to endothelial cells. ICAM-1, VCAM-1, and E-selectin are endothelial adhesion proteins, which can be regulated by cytokines or other inflammatory mediators (13). Kim et al. reported that by decreasing the expression levels of these three endothelial adhesion proteins, leukocyte adhesion to endothelial cells could be reduced (45). In the present study, vitexin significantly reduced the expression of these adhesion proteins and also had a down-regulatory effect on adherent leukocytes, which indicates that vitexin exerts its protective effects on SE partially through the inhibition of leukocyte-endothelial adhesion.

The release of cytokines into the circulation is the central to the early development and persistence of sepsis. Proinflammatory molecules including MCP-1, IL-6, and IL-8, and anti-inflammatory molecules, such as IL-10, are always involved in inflammatory and immune reactions, exerting totally opposite effects (46,47). NF-κB is a general transcription factor involved in regulating the gene expression of cytokines and inflammation-related genes. Inhibiting the excessive activation of NF-κB is an effective way of controlling inflammation-related diseases, like sepsis. A study by Park et al. showed that inhibition of NF-κB suppressed severe LPS-induced sepsis (48). The proinflammatory cytokine TNF-α has a crucial responsibility in cytokine cascade activation, which macrophages release in response to infection, and stimulating the production of downstream cytokines such as IL-6 and IL-8. Previous research has demonstrated that in sepsis and septic shock models, elevated levels of TNF-α are associated with mortality (49). In this study, all of the above proinflammatory cytokines were increased in the CLP mice, which is consistent with previous research. More importantly, vitexin could significantly neutralize their harmful effects and also exerted a protective effect in SE.

Overall, our study suggests that vitexin effectively alleviates SE by inhibiting leukocyte-endothelium adhesion and proinflammatory cytokine expression. However, the pathogenesis of sepsis-associated encephalopathy (SAE) is multifactorial, involving neurotransmitter alterations, inflammatory cytokines, oxidative damage, mitochondrial dysfunction, apoptosis, and other factors. Importantly, oxidative stress may promote the pathogenesis of SAE by enhancing the expression of proinflammatory cytokines, promoting apoptosis, and/or interfering with blood–brain barrier function (50,51). Early sepsis is associated with a decrease in mitochondrial ATP generation, which is likely mediated by cytokines, reactive oxygen species (ROS), and nitric oxide (NO) (52). From the molecular structure of vitamin, it can be found that vitexin has strong antioxidant properties. Importantly, previous research has exhibited that Vitexin is an active component from medicinal plants which has antioxidant and anti-inflammatory activities. Vitexin exhibits an analgesic effect in a variety of inflammatory pain models by targeting TRPV1 and oxidative stress and by modulating cytokine production (53). The inhibiting role of Vitexin on NLRP3 inflammasome may via Nr2-mediated reduction of ROS production (54). So whether
the anti-inflammatory function of vitexin works through antioxidants. This requires us to do further experiments to verify the pharmacological mechanism of vitexin.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the ARRIVE reporting checklist. Available at http://dx.doi.org/10.21037/apm-20-1211

Data Sharing Statement: Available at http://dx.doi.org/10.21037/apm-20-1211

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/apm-20-1211). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The Committee for Animal Experiments of The Second Clinical Medical School Affiliated to North Sichuan Medical College/Nanchong Central Hospital approved all of the experiments involving animals (No. 2017-44). This study also conformed to the NIH guidelines for the care and use of animals.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References
